Pricing Log in Create free account
Friday 6 November 2026 Export BIO’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.8%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

382.51 13.51 +3.66%
Market cap
$9.9B
P/E
10.0×
Fwd P/E
44.7×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bio-Rad Laboratories, Inc. 10-Q filed Aug 4, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:20 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 30, 2026: 9 added · 1 removed · 19 modified; 7 with only figures updated

  1. Modified

    This discussion should be read in conjunction with the information contained in both our consolidated financial statements for the year ended December 31, 2025 and the condensed consolidated financial statements for the three and six months ended March 31June 30, 2026.